Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial

Primary Endpoint ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Faculty of 1000 evaluation for Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717976445.793471388 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

BMC Cancer ◽

10.1186/1471-2407-13-164 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 15

Author(s):

Lucia Del Mastro ◽

Alessandra Fabi ◽

Mauro Mansutti ◽

Michele De Laurentiis ◽

Antonio Durando ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Trial ◽

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70439-5 ◽

2014 ◽

Vol 15 (11) ◽

pp. 1269-1278 ◽

Cited By ~ 82

Author(s):

Gunter von Minckwitz ◽

Fabio Puglisi ◽

Javier Cortes ◽

Eduard Vrdoljak ◽

Norbert Marschner ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Locally Recurrent ◽

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

The Lancet Oncology ◽

10.1016/s1470-2045(12)70566-1 ◽

2013 ◽

Vol 14 (2) ◽

pp. 125-133 ◽

Cited By ~ 59

Author(s):

Istvan Lang ◽

Thomas Brodowicz ◽

Larisa Ryvo ◽

Zsuzsanna Kahan ◽

Richard Greil ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Abstract P1-14-07: Randomized phase 3 study of anthracycline-containing regimens versus S-1 as first-line treatment for metastatic breast cancer (SELECT BC-CONFIRM)–A combined analysis of two randomized phase 3 studies (SELECT BC-CONFIRM and SELECT BC)–

10.1158/1538-7445.sabcs18-p1-14-07 ◽

2019 ◽

Author(s):

Y Park ◽

H Akabane ◽

T Watanabe ◽

M Takahashi ◽

Y Sagara ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Phase 3 ◽

Combined Analysis ◽

Open label, comparative, randomised, multicentre study of trastuzumab given with docetaxel versus sequential single agent therapy with trastuzumab followed by docetaxel as first-line treatment for Her2neu+++ metastatic breast cancer patients

http://isrctn.org/> ◽

10.1186/isrctn13770586 ◽

2012 ◽

Author(s):

J.G.M. Klijn

Keyword(s):

Breast Cancer ◽

Single Agent ◽

Metastatic Breast ◽

Line Treatment ◽

Breast Cancer Patients ◽

First Line ◽

Open Label ◽

Single Agent Therapy ◽

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

European Journal of Cancer ◽

10.1016/j.ejca.2014.10.008 ◽

2014 ◽

Vol 50 (18) ◽

pp. 3077-3088 ◽

Cited By ~ 16

Author(s):

S.W. Lam ◽

S.M. de Groot ◽

A.H. Honkoop ◽

A. Jager ◽

A.J. ten Tije ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Locally Recurrent ◽

Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3238-6 ◽

2014 ◽

Vol 149 (1) ◽

pp. 171-179 ◽

Cited By ~ 43

Author(s):

Michael R. Clemens ◽

Oleg A. Gladkov ◽

Elaina Gartner ◽

Vladimir Vladimirov ◽

John Crown ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Randomized Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer

PLoS ONE ◽

10.1371/journal.pone.0227256 ◽

2020 ◽

Vol 15 (4) ◽

pp. e0227256

Author(s):

Cynthia Huang Bartlett ◽

Jack Mardekian ◽

Matthew James Cotter ◽

Xin Huang ◽

Zhe Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Real World ◽

Metastatic Breast ◽

Progression Free Survival ◽

Line Treatment ◽

First Line ◽

Phase 3 ◽

Free Survival ◽

Randomized open-label phase III multicenter trial comparing TAXOL®/doxorubicin (AT) versus 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(99)81676-1 ◽

1999 ◽

Vol 35 ◽

pp. S314 ◽

Cited By ~ 10

Author(s):

A. Płuż;zańska ◽

J. Jassem ◽

S. Jelič ◽

V. Gorbunova ◽

Z. Mrsič-Krmpotič ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Multicenter Trial ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽